Educational Opportunities

This course includes: 

• Video presentation by a leading expert
• Pre- and post-exams to measure your understanding
• CME and MOC claiming online

Mark Molitch, MD 

Mark Molitch, MD, is Professor Emeritus in the Division of Endocrinology, Metabolism and Molecular Medicine at the Northwestern University Feinberg School of Medicine. He has participated in clinical research for many years, focusing on the pathogenesis of pituitary tumors and their treatment. He has also had a long-standing interest in the interaction between pituitary tumors and pregnancy. He has been involved in most of the initial trials of therapeutic agents for pituitary tumors, including those using bromocriptine, mesulergine, quinagolide, cabergoline, octreotide, octreotide-LAR, oral octreotide, lanreotide and mifepristone. He was also PI of the Northwestern University Center of The Testosterone Trials. Dr. Molitch has been a member of the committees that wrote many current clinical guidelines used by endocrinologists, including those for Adult Growth Hormone Deficiency, Prolactinomas, Acromegaly, Pituitary Incidentalomas, Diabetes (Standards of Care), and Diabetic Nephropathy. In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 500 original papers, review articles, book chapters, case reports and other publications. In 1997, Dr. Molitch was the recipient of the “Outstanding Physician Educator in the Field of Diabetes Award” by the American Diabetes Association and in 2013 was the recipient of the “Distinguished Educator Award” of The Endocrine Society and was President of the Pituitary Society in 2012-2013. 

LEARNING OBJECTIVES

Upon completion of this activity, learners will be able to:

• Describe the risks to the fetus of using bromocriptine and cabergoline to allow ovulation to occur and then stopping the medication
• Describe the risk of tumor enlargement during pregnancy in patients with micro- and macro-prolactinomas
• At the conclusion of this presentation, the attendee will be able to: List 3 reasons why patients with acromegaly might be infertile.

MAINTENANCE OF CERTIFICATION

Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. 

Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.

ACCREDITATION AND DESIGNATION STATEMENTS

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.